Drug intelligence / Profile preview

DKP106

Development stage: Preclinical
Lead developer: Dongkwang Pharm
Modality: Small Molecules

Overview

DKP106 is a small molecule drug candidate being developed by Dongkwang for the treatment of diabetes. It is categorized as an "improved new drug" (개량신약) in South Korea, a designation typically given to products that offer improvements in safety, efficacy, or convenience over existing approved drugs through modifications such as new formulations, salts, or combinations. As of 2024, the specific active pharmaceutical ingredient and its molecular target have not been publicly disclosed. The project is currently in the preclinical or early development stage.

Beyond the preview

Go deeper on DKP106.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DKP106.

Explore the full profile